A biological terrorist attack probably would first be detected by doctors or other health-care workers. The speed of a response would then depend on their rapid recognition and communication that certain illnesses appeared out of the ordinary. For this reason, preparing for biological terrorism has more in common with confronting the threat of emerging infectious diseases than with preparing for chemical or nuclear attacks. Defense against bioterrorism, like protection against emerging diseases, must therefore rely on improved national and international public-health surveillance. Too often, thinking about bioterrorism has mimicked thinking about chemical terrorism, a confusion that leads to an emphasis on the wrong approaches in preparing to meet the threat.

Future regional conflicts will almost certainly involve politically less stable nations or other regional actors using theater ballistic missiles armed with either nuclear, biological, or chemical warheads. The United States Air Force is attempting to deal with this threat by developing the Airborne Laser (ABL) with the goal of shooting down missiles while they are still under power and before they can release submunitions possibly containing highly toxic biological agents. This paper presents the results of an analysis of this system. It is based solely on information found in the open literature and using the basic physics and engineering involved in transmitting intense laser beams through the atmosphere. The ABL's potential capabilities and possible theaters of operation are discussed at a non-technical level.